










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Meta-analysis	 results	 of	 up	 to	342,415	 individuals	of	 European	ancestry	 for	 SBP	and	DBP:	 Established	17	




the	coded	allele	 (that	 is	 the	allele	coded	0,	1,	2)	under	an	additive	genetic	model.	“*”	 in	the	 lead	SNP	22	
column	 indicates	 a	 non-synonymous	 coding	 SNP	 (either	 the	 SNP	 itself	 or	 another	 SNP	 in	 r2	 >0.8).	 #	23	
Established	loci	have	smaller	total	sample	sizes	relative	to	novel	loci	(see	Supplementary	Note).	24	
Table	2.		Overview	of	novel	and	known	BP	variant	properties.	25	
Key	characteristics	of	 the	novel	and	established	BP	 loci	 are	 shown.	MAF	and	effect	 size	estimates	are	26	
derived	from	the	Cardio-MetaboChip	data.		Variance	explained	estimates	are	estimated	from	one	large	27	





Shown	 are	 the	 estimated	 effects	 of	 a	 BP	 risk	 score	 comprised	 of	 up	 to	 66	 SNPs	 (see	 column	 “Total	2	
#SNPs”)	 on	 risk	 of	 dichotomous	 outcome	 (as	 odds	 ratios)	 or	 increment	 in	 continuous	 measures	 per	3	
predicted	mmHg	of	the	SBP	or	DBP	score.		The	effect	sizes	are	expressed	as	incremental	change	in	the	4	
phenotype	for	quantitative	traits	and	natural	logarithm	of	the	odds	ratio	for	binary	traits,	per	1	mmHg	5	




was	<	0.0028	 (see	Supplementary	Note).	 	The	number	of	SNPs	 removed	when	calculating	 the	pruned	10	
results	 is	 indicated	by	 “#	 SNPs	 rem.”.	 	 The	 results	 per	 individual	 SNP	 can	be	 found	 in	Supplementary	11	
Table	15.		CAD:	coronary	artery	disease,	LV:	left	ventricle,	CKD:	chronic	kidney	disease,	eGFR:	estimated	12	













Traits	 SBP		 		 	DBP	
Effect	 SE	 P	value	 Total	N	 		 Effect	 SE	 P	value	 Total	N#	
NEW	1	 HIVEP3	 rs7515635	 1	 42,408,070	 T/C	 0.468	 SBP	 0.307	 0.0444	 4.81E-12	 340,969	 		 0.1365	 0.0263	 2.05E-07	 340,934	
NEW	2	 PNPT1	 rs1975487	 2	 55,809,054	 A/G	 0.464	 DBP	 -0.2107	 0.045	 2.81E-06	 337,522	 	 -0.1602	 0.0266	 1.75E-09	 337,517	
NEW	3	 FGD5	 rs11128722	 3	 14,958,126	 A/G	 0.563	 SBP	&	DBP	 -0.3103	 0.0469	 3.61E-11	 310,430	 		 -0.1732	 0.0279	 5.16E-10	 310,429	
NEW	4	 ADAMTS9	 rs918466	 3	 64,710,253	 A/G	 0.406	 DBP	 -0.0865	 0.0459	 5.94E-02	 336,671	 	 -0.1819	 0.027	 1.73E-11	 336,653	
NEW	5	 TBC1D1-FLJ13197	 rs2291435	 4	 38,387,395	 T/C	 0.524	 SBP	&	DBP	 -0.3441	 0.0449	 1.90E-14	 331,382	 		 -0.156	 0.0266	 4.26E-09	 331,389	
NEW	6	 TRIM36	 rs10077885	 5	 114,390,121	 A/C	 0.501	 SBP	&	DBP	 -0.284	 0.0444	 1.64E-10	 338,328	 	 -0.1735	 0.0263	 3.99E-11	 338,323	
NEW	7	 CSNK1G3	 rs6891344	 5	 123,136,656	 A/G	 0.819	 DBP	 0.2811	 0.058	 1.24E-06	 338,688	 		 0.2311	 0.0343	 1.58E-11	 338,678	
NEW	8	 CHST12-LFNG	 rs2969070	 7	 2,512,545	 A/G	 0.639	 SBP	&	DBP	 -0.2975	 0.0464	 1.44E-10	 335,991	 	 -0.1821	 0.0274	 2.92E-11	 335,972	
NEW	9	 ZC3HC1	 rs11556924
*	
7	 129,663,496	 T/C	 0.384	 SBP	&	DBP	 -0.2705	 0.0468	 7.64E-09	 325,929	 		 -0.2141	 0.0276	 8.15E-15	 325,963	
NEW	10	 PSMD5	 rs10760117	 9	 123,586,737	 T/G	 0.415	 SBP	 0.283	 0.0457	 6.10E-10	 333,377	 	 0.0999	 0.0269	 2.08E-04	 333,377	
NEW	11	 DBH	 rs6271*	 9	 136,522,274	 T/C	 0.072	 SBP	&	DBP	 -0.5911	 0.0899	 4.89E-11	 306,394	 		 -0.4646	 0.0532	 2.42E-18	 306,463	
NEW	12	 RAPSN,	PSMC3,	SLC39A13	 rs7103648	 11	 47,461,783	 A/G	 0.614	 SBP	&	DBP	 -0.3349	 0.0462	 4.43E-13	 335,614	 	 -0.2409	 0.0272	 9.03E-19	 335,592	
NEW	13	 LRRC10B	 rs751984	 11	 61,278,246	 T/C	 0.879	 SBP	&	DBP	 0.4074	 0.0691	 3.80E-09	 334,583	 		 0.3755	 0.0409	 4.20E-20	 334,586	
NEW	14	 SETBP1	 rs12958173	 18	 42,141,977	 A/C	 0.306	 SBP	&	DBP	 0.3614	 0.0489	 1.43E-13	 331,007	 	 0.1789	 0.0289	 5.87E-10	 331,010	
NEW	15	 INSR	 rs4247374	 19	 7,252,756	 T/C	 0.143	 SBP	&	DBP	 -0.5933	 0.0673	 1.23E-18	 302,458	 		 -0.3852	 0.0396	 2.08E-22	 302,459	
NEW	16	 ELAVL3	 rs17638167	 19	 11,584,818	 T/C	 0.047	 DBP	 -0.4784	 0.1066	 7.13E-06	 333,137	 	 -0.3479	 0.0632	 3.71E-08	 333,107	
NEW	17	 CRYAA-SIK1	 rs12627651	 21	 44,760,603	 A/G	 0.288	 SBP	&	DBP	 0.3905	 0.0513	 2.69E-14	 310,738	 		 0.2037	 0.0301	 1.36E-11	 310,722	
EST	1	 CASZ1	 rs880315	 1	 10,796,866	 T/C	 0.641	 SBP	&	DBP	 -0.475	 0.062	 2.09E-14	 184,226	 	 -0.257	 0.038	 1.34E-11	 184,212	
EST	2	 MTHFR-NPPB	 rs17037390
*	
1	 11,860,843	 A/G	 0.155	 SBP	&	DBP	 -0.908	 0.081	 5.95E-29	 195,493	 		 -0.499	 0.05	 1.20E-23	 195,481	
EST	3	 ST7L-CAPZA1-MOV10	 rs1620668	 1	 113,023,980	 A/G	 0.822	 SBP	&	DBP	 -0.535	 0.076	 1.45E-12	 197,966	 	 -0.285	 0.047	 9.00E-10	 197,948	
EST	4	 MDM4	 rs4245739	 1	 204,518,842	 A/C	 0.737	 DBP	 0.326	 0.068	 1.37E-06	 191,594	 		 0.243	 0.041	 4.63E-09	 191,578	
EST	5	 AGT	 rs2493134*	 1	 230,849,359	 T/C	 0.579	 SBP	&	DBP	 -0.413	 0.058	 9.65E-13	 199,505	 	 -0.275	 0.036	 9.53E-15	 199,502	
EST	6	 KCNK3	 rs2586886	 2	 26,932,031	 T/C	 0.599	 SBP	&	DBP	 -0.404	 0.059	 5.94E-12	 197,269	 		 -0.254	 0.036	 1.92E-12	 197,272	
EST	7	 NCAPH	 rs772178	 2	 96,963,684	 A/G	 0.64	 DBP	 -0.072	 0.061	 2.39E-01	 192,513	 	 -0.208	 0.038	 3.58E-08	 192,501	
EST	8	 FIGN-GRB14	 rs1371182	 2	 165,099,215	 T/C	 0.443	 SBP	&	DBP	 -0.444	 0.058	 1.89E-14	 196,262	 		 -0.252	 0.036	 1.50E-12	 196,240	
EST	9	 HRH1-ATG7	 rs2594992	 3	 11,360,997	 A/C	 0.607	 SBP	 -0.334	 0.06	 2.31E-08	 189,895	 	 -0.136	 0.037	 2.20E-04	 189,854	
EST	10	 SLC4A7	 rs711737	 3	 27,543,655	 A/C	 0.604	 SBP	 0.334	 0.058	 9.93E-09	 200,282	 		 0.17	 0.036	 2.24E-06	 200,260	
EST	11	 ULK4	 rs2272007*	 3	 41,996,136	 T/C	 0.18	 DBP	 -0.11	 0.077	 1.52E-01	 193,915	 	 0.328	 0.047	 3.94E-12	 193,900	
EST	12	 MAP4	 rs6442101*	 3	 48,130,893	 T/C	 0.692	 SBP	&	DBP	 0.396	 0.062	 1.62E-10	 200,543	 		 0.303	 0.038	 1.60E-15	 200,534	
EST	13	 MECOM	 rs6779380	 3	 169,111,915	 T/C	 0.539	 SBP	&	DBP	 -0.439	 0.06	 1.85E-13	 186,535	 	 -0.239	 0.037	 6.87E-11	 186,521	
EST	14	 FGF5	 rs1458038	 4	 81,164,723	 T/C	 0.3	 SBP	&	DBP	 0.659	 0.065	 5.36E-24	 188,136	 		 0.392	 0.04	 7.36E-23	 188,088	
EST	15	 ARHGAP24	 rs17010957	 4	 86,719,165	 T/C	 0.857	 SBP	 -0.498	 0.082	 1.51E-09	 196,325	 	 -0.173	 0.051	 6.63E-04	 196,292	
EST	16	 SLC39A8	 rs13107325
*	
4	 103,188,709	 T/C	 0.07	 SBP	&	DBP	 -0.837	 0.127	 4.69E-11	 175,292	 		 -0.602	 0.078	 1.63E-14	 175,372	
EST	17	 GUCY1A3-GUCY1B3	 rs4691707	 4	 156,441,314	 A/G	 0.652	 SBP	 -0.349	 0.06	 7.10E-09	 198,246	 	 -0.163	 0.037	 1.08E-05	 198,226	
EST	18	 NPR3-C5orf23	 rs12656497	 5	 32,831,939	 T/C	 0.403	 SBP	&	DBP	 -0.487	 0.06	 3.85E-16	 194,831	 		 -0.228	 0.037	 4.73E-10	 194,829	
EST	19	 EBF1	 rs11953630	 5	 157,845,402	 T/C	 0.366	 SBP	&	DBP	 -0.38	 0.065	 3.91E-09	 167,698	 	 -0.23	 0.04	 8.07E-09	 167,708	
EST	20	 HFE	 rs1799945*	 6	 26,091,179	 C/G	 0.857	 SBP	&	DBP	 -0.598	 0.086	 3.28E-12	 185,306	 		 -0.43	 0.053	 3.10E-16	 185,273	
EST	21	 BAT2-BAT5	 rs2187668	 6	 32,605,884	 T/C	 0.126	 DBP	 -0.291	 0.092	 1.60E-03	 189,806	 	 -0.372	 0.057	 4.31E-11	 189,810	
EST	22	 ZNF318-ABCC10	 rs6919440	 6	 43,352,898	 A/G	 0.57	 SBP	 -0.337	 0.058	 4.92E-09	 200,733	 		 -0.125	 0.035	 4.25E-04	 200,730	
EST	23	 RSPO3	 rs1361831	 6	 127,181,089	 T/C	 0.541	 SBP	&	DBP	 -0.482	 0.058	 7.38E-17	 197,027	 	 -0.271	 0.036	 2.34E-14	 197,012	
EST	24	 PLEKHG1	 rs17080093	 6	 150,997,440	 T/C	 0.075	 DBP	 -0.564	 0.111	 3.83E-07	 194,728	 		 -0.411	 0.068	 1.71E-09	 194,734	
EST	25	 HOTTIP-EVX	 rs3735533	 7	 27,245,893	 T/C	 0.081	 SBP	&	DBP	 -0.798	 0.106	 6.48E-14	 197,881	 	 -0.445	 0.065	 1.09E-11	 197,880	
EST	26	 PIK3CG	 rs12705390	 7	 106,410,777	 A/G	 0.227	 SBP	 0.619	 0.069	 2.69E-19	 198,297	 		 0.059	 0.042	 1.63E-01	 198,290	
EST	27	 BLK-GATA4	 rs2898290	 8	 11,433,909	 T/C	 0.491	 SBP	 0.377	 0.058	 8.85E-11	 197,759	 	 0.167	 0.036	 3.17E-06	 197,726	
EST	28	 CACNB2	 rs12243859	 10	 18,740,632	 T/C	 0.326	 SBP	&	DBP	 -0.402	 0.061	 6.13E-11	 199,136	 		 -0.335	 0.038	 8.11E-19	 199,124	
EST	29	 C10orf107	 rs7076398	 10	 63,533,663	 A/T	 0.188	 SBP	&	DBP	 -0.563	 0.076	 1.72E-13	 187,013	 	 -0.409	 0.047	 2.55E-18	 187,024	
EST	30	 SYNPO2L	 rs12247028	 10	 75,410,052	 A/G	 0.611	 SBP	 -0.364	 0.063	 8.16E-09	 180,194	 		 -0.159	 0.039	 3.89E-05	 180,094	
EST	31	 PLCE1	 rs932764*	 10	 95,895,940	 A/G	 0.554	 SBP	&	DBP	 -0.495	 0.059	 6.88E-17	 195,577	 	 -0.224	 0.036	 6.28E-10	 195,547	
EST	32	 CYP17A1-NT5C2	 rs943037	 10	 104,835,919	 T/C	 0.087	 SBP	&	DBP	 -1.133	 0.105	 2.35E-27	 193,818	 		 -0.482	 0.064	 4.48E-14	 193,799	
EST	33	 ADRB1	 rs740746	 10	 115,792,787	 A/G	 0.73	 SBP	&	DBP	 0.486	 0.067	 4.59E-13	 184,835	 	 0.32	 0.041	 8.63E-15	 184,868	
EST	34	 LSP1-TNNT3	 rs592373	 11	 1,890,990	 A/G	 0.64	 SBP	&	DBP	 0.484	 0.063	 2.02E-14	 177,149	 		 0.282	 0.039	 3.61E-13	 177,134	
EST	35	 ADM	 rs1450271	 11	 10,356,115	 T/C	 0.468	 SBP	&	DBP	 0.413	 0.059	 3.40E-12	 191,246	 	 0.199	 0.036	 4.11E-08	 191,221	
EST	36	 PLEKHA7	 rs1156725	 11	 16,307,700	 T/C	 0.804	 SBP	&	DBP	 -0.447	 0.072	 5.65E-10	 200,889	 		 -0.292	 0.044	 3.67E-11	 200,899	
EST	37	 SIPA1	 rs3741378*	 11	 65,408,937	 T/C	 0.137	 SBP	 -0.486	 0.084	 8.04E-09	 194,563	 	 -0.183	 0.052	 4.17E-04	 194,551	
EST	38	 FLJ32810-TMEM133	 rs633185	 11	 100,593,538	 C/G	 0.715	 SBP	&	DBP	 0.522	 0.067	 6.97E-15	 183,845	 		 0.288	 0.041	 2.38E-12	 183,825	
EST	39	 PDE3A	 rs3752728	 12	 20,192,972	 A/G	 0.737	 DBP	 0.331	 0.066	 4.32E-07	 200,440	 		 0.319	 0.04	 2.35E-15	 200,408	
EST	40	 ATP2B1	 rs11105354	 12	 90,026,523	 A/G	 0.84	 SBP	&	DBP	 0.909	 0.081	 3.88E-29	 195,206	 	 0.459	 0.05	 2.61E-20	 195,195	
EST	41	 SH2B3	 rs3184504*	 12	 111,884,608	 T/C	 0.475	 SBP	&	DBP	 0.498	 0.062	 9.97E-16	 177,067	 		 0.362	 0.038	 1.28E-21	 177,122	
EST	42	 TBX5-TBX3	 rs2891546	 12	 115,552,499	 A/G	 0.11	 DBP	 -0.529	 0.1	 1.36E-07	 172,012	 	 -0.38	 0.061	 4.71E-10	 171,980	
EST	43	 CYP1A1-ULK3	 rs936226	 15	 75,069,282	 T/C	 0.722	 SBP	&	DBP	 -0.549	 0.067	 3.06E-16	 187,238	 		 -0.363	 0.041	 1.03E-18	 187,221	
EST	44	 FURIN-FES	 rs2521501	 15	 91,437,388	 A/T	 0.684	 SBP	&	DBP	 -0.639	 0.069	 3.35E-20	 164,272	 	 -0.358	 0.042	 1.85E-17	 164,255	
EST	45	 PLCD3	 rs7213273	 17	 43,155,914	 A/G	 0.658	 SBP	 -0.413	 0.066	 4.71E-10	 164,795	 		 -0.185	 0.041	 7.23E-06	 164,788	
EST	46	 GOSR2	 rs17608766	 17	 45,013,271	 T/C	 0.854	 SBP	 -0.658	 0.083	 2.27E-15	 188,895	 	 -0.218	 0.051	 1.95E-05	 188,928	
EST	47	 ZNF652	 rs12940887	 17	 47,402,807	 T/C	 0.38	 DBP	 0.321	 0.06	 7.06E-08	 192,546	 		 0.261	 0.037	 1.07E-12	 192,524	
EST	48	 JAG1	 rs1327235	 20	 10,969,030	 A/G	 0.542	 SBP	&	DBP	 -0.395	 0.059	 2.23E-11	 192,680	 	 -0.308	 0.036	 1.78E-17	 192,659	
















Variance	explained	SBP	 0.52%	 2.95%	 3.46%	














































61	 1.042	 1.72E-44	 1.75E-25	 4.08E-32	 10	 		 1.069	 1.19E-42	 6.63E-27	 2.2E-38	 10	
heart	failure	 dich.	 EUR	 CHARGE	 2,526	
/18,400		
66	 1.021	 2.77E-02	 1.63E-01	 2.77E-02	 0	 	 1.035	 2.31E-02	 1.70E-01	 2.31E-02	 0	
LV	mass	 cont.	 EUR	 CHARGE	 11,273	 66	 0.480	 6.43E-04	 3.58E-01	 6.43E-04	 0	 		 0.754	 1.23E-03	 3.21E-01	 1.23E-03	 0	
LV	wall	thickness	 cont.	 EUR	 CHARGE	 11,311	 66	 0.004	 4.45E-06	 5.83E-02	 4.45E-06	 0	 		 0.007	 3.19E-06	 6.40E-02	 3.19E-06	 0	
KIDNEY	 		 		 		 		 		 	 	 	 		 		 		 	 	 	 		 		
CKD		 dich.	 EUR	 CHARGE	 6,271	
/68,083	
65	 1.010	 1.37E-01	 1.77E-03	 2.65E-01	 1	 	 1.008	 4.49E-01	 1.25E-03	 7.69E-01	 1	
eGFR	(based	on	cr)		 cont.	 EUR	 CHARGE		 74,354	 65	 0.000	 7.07E-01	 3.12E-05	 3.22E-01	 2	 		 0.000	 9.41E-01	 3.02E-05	 9.65E-01	 2	
eGFR	(based	on	
cystatin)		
cont.	 EUR	 CHARGE	 74,354	 65	 0.001	 9.05E-02	 9.28E-06	 4.11E-01	 1	 		 0.001	 3.30E-01	 5.64E-06	 6.9E-01	 1	
creatinine		 cont.	 EUR	 KidneyGE
N	
23,812	 66	 0.000	 9.42E-01	 6.31E-03	 9.42E-01	 0	 		 0.000	 4.11E-01	 7.16E-03	 4.11E-01	 0	
microalbuminuria		 dich.	 EUR	 CHARGE	 2,499	
/29,081	
65	 0.011	 2.10E-01	 4.79E-02	 2.1E-01	 0	 	 0.023	 1.02E-01	 5.66E-02	 1.02E-02	 0	
urinary	albumin/cr	
ratio	
cont.	 EUR	 CHARGE	 31,580	 65	 0.009	 2.52E-03	 3.02E-04	 0.53E-03	 1	 		 0.015	 2.40E-03	 3.08E-04	 8.31E-03	 1	
STROKE	 		 		 		 		 		 	 	 	 		 		 		 	 	 	 		 		
stroke,	all	subtypes	 dich.	 EUR	 CHARGE	 1,544	
/18,058	
66	 0.056	 6.11E-06	 8.26E-02	 6.11E-06	 0	 	 0.085	 3.79E-05	 4.98E-02	 3.79E-05	 0	
stroke,	ischemic	
subtype	
dich.	 EUR	 CHARGE	 1,164	
/18,438	







66	 0.036	 1.69E-10	 4.72E-02	 1.69E-10	 0	 	 0.056	 1.29E-09	 2.51E-02	 1.29E-09	 0	
VASCULATURE	 		 		 		 		 	 	 	 		 		 		 	 	 	 		 		
cIMT	 cont.	 EUR	 CHARGE	 27,610	 66	 0.004	 4.80E-15	 5.06E-08	 7.32E-10	 4	 		 0.005	 4.15E-11	 3.84E-10	 6.2E-07	 5	
EYE	 		 		 		 		 		 	 	 	 		 		 		 	 	 	 		 		
mild	retinop.	 dich.	 EUR	 CHARGE	 1,122	
/18,289	
66	 1.021	 1.37E-01	 6.01E-03	 1.37E-01	 0	 	 1.046	 5.78E-02	 7.81E-03	 5.78E-02	 0	
central	retinal	artery	
caliber	
cont.	 EUR	 CHARGE	 18,576	 66	 0.343	 3.29E-14	 2.56E-06	 2.06E-13	 2	 		 0.570	 3.61E-14	 2.44E-06	 7.05E-13	 3	
mild	retinop.	 dich.	 EAS	 SEED	 289	
/5,419	
66	 1.033	 2.55E-01	 2.42E-01	 2.55E-01	 0	 	 1.087	 8.55E-02	 2.87E-01	 8.55E-02	 0	
central	retinal	artery	
caliber	























































Multivariable	 regression	 modeling	 was	 performed	 for	 each	 possible	 combination	 of	 putative	 6	
independent	SNPs	from	a)	model	selection	implemented	in	GCTA-COJO	and	b)	a	comprehensive	manual	 7	
review	of	 the	 literature	 (Supplementary	Table	9).	 	Any	SNP	with	P	 <	5x10-8	 in	a	previous	 reported	BP	 8	
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